Main menu
Edison Group
  • Home
  • Sparks
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Metals One

    MCap

    —

    Last close

    GBP0.01

    ▲ 0.18 (19.44%)

    Edesa Biotech

    MCap

    USD41m

    Last close

    USD4.21

    ▲ 0.65 (18.26%)

    Card Factory

    MCap

    GBP290m

    Last close

    GBP0.88

    ▲ 9.70 (12.45%)

  • Sectors

    Sectors

    View All Sectors
  • Megatrends

    Megatrends

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sparks commentary - Immix Biopharma

Healthcare

Sparks - Immix Biopharma

More on this equity
Scientist using protective robber gloves for handling substances and experiments
Immix Biopharma (NASDAQ: IMMX) closes $125m raise, backing NXC-201’s next steps
Published by Arron Aatkar, PhD

Immix has closed its $125m equity offering, issuing 11.36m shares at $11 each and receiving approximately $117.1m after costs. Proceeds will finance NXC-201 development and general corporate needs. The financing follows a NEXICART-2 interim readout showing an 89% complete response rate across 45 patients with relapsed/refractory amyloid light chain amyloidosis; longer follow-up will provide an incremental assessment of durability.

As communicated on the company’s recent webcast (discussed here), management expects the raise to extend its cash runway to Q129, assuming no revenue, beyond the planned mid-2027 final readout and biologics licence application to the FDA.

Next Sparks Commentary in this sector >

Latest

Consumer | Comment

PZ Cussons (LSE: PZC) – Reassuring Q127 trading update

Healthcare | Comment

Mendus (OMX: IMMU) updates five-year ADVANCE II data and CML progress

Healthcare | Comment

AOTI (AIM: AOTI) reports strong H1, Medicare catalyst draws closer

Healthcare | Comment

Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) – H1 growth accelerates as restructuring bears fruit

Consumer | Comment

Shepherd Neame (AQSE: SHEP) – Pubs drive progress as brewing strategy comes under review
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.